Pancreatic Ductal Adenocarcinoma Pipeline Report 2016 - Review of 24 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Pancreatic Ductal Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Ductal Adenocarcinoma and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Pancreatic Ductal Adenocarcinoma Overview
  3. Therapeutics Development
  4. Pipeline Products for Pancreatic Ductal Adenocarcinoma - Overview
  5. Pipeline Products for Pancreatic Ductal Adenocarcinoma - Comparative Analysis
  6. Pancreatic Ductal Adenocarcinoma - Therapeutics under Development by Companies
  7. Pancreatic Ductal Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes
  8. Pancreatic Ductal Adenocarcinoma Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Pancreatic Ductal Adenocarcinoma - Products under Development by Companies
  13. Pancreatic Ductal Adenocarcinoma - Products under Investigation by Universities/Institutes
  14. Pancreatic Ductal Adenocarcinoma - Companies Involved in Therapeutics Development
  • AbbVie Inc.
  • BerGenBio AS
  • Celgene Corporation
  • Clovis Oncology, Inc.
  • Coare Biotechnology, Inc.
  • Concordia Healthcare Corp.
  • FibroGen, Inc.
  • Forty Seven Inc.
  • Gilead Sciences, Inc.
  • Halozyme Therapeutics, Inc.
  • Immodulon Therapeutics Ltd.
  • Immunomedics, Inc.
  • Incuron, LLC
  • Incyte Corporation
  • Inovio Pharmaceuticals, Inc.
  • MedImmune, LLC
  • Medisyn Technologies, Inc.
  • Merck & Co., Inc.
  • Nerviano Medical Sciences S.r.l.
  • OncoMed Pharmaceuticals, Inc.
  • Oryx GmbH & Co. KG
  • Sillajen Biotherapeutics
  • Tara Immuno-Oncology Therapeutics LLC
  • Tokai Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/8gv7jj/pancreatic_ductal

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pancreatic Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pancreatic Cancer Drugs